AuthorisedTherapeutic exploratory (Phase II)Interventional

Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly

Acromegaly is a condition where the body makes too much growth hormone. One treatment is a long-acting injection called pasireotide, which is given once a month. However, this medicine does not work for everyone, and it usually takes several months to see if it is helping. This study looks at a new, quick test using a short-acting version of pasireotide. Patients have a small injection under the skin, and doctors test their blood over the next two to three hours. The goal is to see if early hormone changes can accurately predict whether the monthly treatment will work in the long run. Participants will also have blood tests and an MRI scan, with follow-up over three months. If successful, this test could help doctors choose the right treatment much sooner.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Enrolment target

Start

26 Aug 2026

Acromegaly

What is this study about?

Acromegaly is a rare condition usually caused by a small, non-cancerous growth on the pituitary gland at the base of the brain. This growth makes the body produce too much growth hormone, which can lead to swollen hands and feet, tiredness, joint pain, and other health issues. Doctors often use medicines to bring hormone levels back into balance.

One of these medicines is pasireotide LAR, a slow-release injection given every four weeks. While it works well for some people, it does not work for everyone. At the moment, patients must stay on the treatment for months before doctors can tell if it is truly working. This waiting period can be frustrating and can delay finding a treatment that suits them better.

In this study, researchers are testing a short-acting version of the same medicine. By giving a small, fast-acting injection under the skin and checking hormone levels just two to three hours later, doctors hope to get a quick answer. They want to see if this early dip in growth hormone reliably predicts who will benefit from the long-term medicine.

Participants will also have regular blood tests and an MRI scan to check their pituitary gland. If this short test proves accurate, it could give doctors a simple, reliable way to personalise care, saving time and helping people with acromegaly get the most effective treatment faster.

Key takeaways

Tests whether a quick injection can predict long-term success with pasireotide.
Aims to replace months of trial-and-error with a two-to-three-hour blood test.
Open to adults aged 18 and older diagnosed with acromegaly.
Involves short-acting injections, blood tests, an MRI scan, and three months of follow-up.
Participation is entirely voluntary and will not affect your standard NHS care.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with acromegaly. Both men and women can take part.

Because the study focuses on how pasireotide affects growth hormone levels, the research team will check your medical history, current hormone levels, and any previous pituitary treatments to see if the study is safe and suitable for you.

Your doctor or the study team will talk through all the entry criteria with you before you agree to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged 18 or older.
I have been diagnosed with acromegaly.
I am willing to have injections under the skin and multiple blood tests.
I am able to attend clinic visits over a three-month period.
I am safe to have an MRI scan (for example, no non-compatible metal implants).

Answer every question to see your result.

What does participation involve?

Taking part in this study involves receiving a short-acting injection of pasireotide just under the skin on two separate days (Day 1 and Day 4). On these days, you will have blood samples taken before the injection and at set times afterwards (up to three hours later) to see how your hormone levels respond. You will also have an MRI scan of your pituitary gland. The research team will track your health and hormone levels over a three-month follow-up period to see how well the early test predicted your response to long-term treatment.

Potential risks and benefits

You may not get a direct medical benefit from this test, but the results could help your doctor decide if pasireotide is the best long-term option for you. Your participation could also help future patients receive the right treatment sooner. Like all medicines, pasireotide can cause side effects. These can include mild stomach aches, nausea, diarrhoea, injection site redness, and changes in blood sugar levels. Your medical team will monitor you closely throughout. Taking part is completely voluntary, and you can leave the study at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Spain

Common questions

What is acromegaly?

It is a condition where the pituitary gland makes too much growth hormone, often leading to changes in body shape, swollen hands or feet, and joint pain.

What is the difference between short-acting and long-acting pasireotide?

The short-acting version stays in the body for only a few hours and is used here for quick testing. The long-acting version is released slowly over a month to treat the condition long term.

Will taking this test cure my acromegaly?

No. This study is testing a check (a diagnostic test) rather than a cure. It aims to predict which treatment will work best for you.

Are the injections painful?

The injections are given just under the skin, similar to an insulin jab. You might feel a brief sting or pinch, and there may be mild redness where you were injected.

What happens if I change my mind?

You can leave the trial at any point. You do not need to give a reason, and it will not affect the standard of care you receive.